Clinical trial NCT05650918: MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Official title: Dendritic Cells Loaded With Allogeneic Tumor Lysate (MesoPher) in Combination With a CD40 Agonist (Mitazalimab) in Metastatic Pancreatic Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Pancreatic Cancer
Keywords: Immunotherapy
CD40 agonist
Dendritic cell therapy
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2022-12-14
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: open-label, dose-finding, single-center phase I study
Primary purpose: OTHER

Brief summary: Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading to exclusion of T cells. The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent and T-cell-independent mechanisms. Targeting the desmoplastic stroma, thereby making the tumor more permeable for T-cell infiltration, is seen as one of the assisting mechanisms. Furthermore, the immunological coldness of pancreatic cancers infers that tumor-reactive T-cell responses are absent or weak at best. Dendritic cell therapy introduces tumor-specific T cells and in combination with a CD40 agonist, may lead to synergistic anti-tumor responses which could be beneficial for pancreatic cancer patients.

Detailed description: Rationale: Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading to exclusion of T cells. The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent and T-cell-independent mechanisms. Targeting the desmoplastic stroma, thereby making the tumor more permeable for T-cell infiltration, is seen as one of the assisting mechanisms. Furthermore, the immunological coldness of pancreatic cancers infers that tumor-reactive T-cell responses are absent or weak at best. Dendritic cell therapy introduces tumor-specific T cells and in combination with a CD40 agonist, may lead to synergistic anti-tumor responses which could be beneficial for pancreatic cancer patients.

Objective: To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic cancer after standard-of-care (SOC) treatment with (modified) FOLFIRINOX.

Study design: Open-label, single-center, phase I dose finding study using a modified toxicity probability interval (mTPI) design.

Study population: Adults with metastatic pancreatic cancer after SOC treatment with (modified) FOLFIRINOX.

Intervention: Leukapheresis is performed after which monocytes are used for differentiation to dendritic cells. Autologous dendritic cells pulsed with an allogeneic tumor lysate (MesoPher) will be administered intra-dermally and intravenously 3 times every 2 weeks. Booster vaccinations are given after 3 and 6 months. On the same day after administration of MesoPher a CD40 agonist (mitazalimab) will be administered intravenously.

Study parameters/endpoints: The main study endpoint are the dose-limiting toxicities of MesoPher/mitazalimab combination therapy. The secondary endpoints are the induced immune responses on therapy and the radiographical response rate according to RECIST and iRECIST.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients have to undergo additional outpatient clinic visits for this study and additional invasive procedures specifically for this trial, e.g. intravenous catheter placement and tumor metastasis biopsies. Although these are invasive procedures, associated risks are limited. Intravenous access is necessary during every visit, i.e. for leukapheresis, for drawing blood samples and for the administration of study medication. Leukapheresis is a standard procedure and will be performed according to our institutional guidelines. Leukapheresis demonstrates a limited risk for transient thrombocytopenia and leukopenia. Previous clinical studies have shown that injection with tumor lysate-pulsed dendritic cells (MesoPher) was well tolerated without major systemic toxicity, with the exception of low-grade flu-like symptoms (REACtiVE Trial, NL67169.000.18; DENIM/MM04: NCT03610360; MM03 NL44330.000.14 / NCT02395679).

Also, intravenous injection of mitazalimab up to 1200 µg/kg was well tolerated with manageable side effects. There are currently no trials investigating this combination therapy. Combining two immunomodulatory drugs increases the risk for toxicity. The objective of this phase I study is to investigate safety and tolerability of administrating MesoPher/mitazalimab combination therapy in metastatic pancreatic cancer patients. Patients may have potential beneficial anti-tumor responses following study medication.

Eligibility criteria: Inclusion Criteria:

* Metastatic pancreatic cancer as defined by the presence of radiologically suspect metastatic lesions.
* Inclusion ≤ 4 weeks after stopping FOLFIRINOX chemotherapy.
* No more than 1 line of chemotherapy for metastatic disease is allowed. Prior FOLFIRINOX for locally advanced disease if given within 1 year before screening will be counted as first-line treatment. Any FOLFIRINOX given in the curative intent setting if more than a year before screening will not be considered first line therapy.
* An accessible metastatic lesion for histological tissue collection.
* Patients must be at least 18 years old and must be able to give written informed consent.
* WHO performance status 0-1.
* Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count \> 1.0 x 109/l, platelet count \> 100 x 109/l, and Hb \> 6.0 mmol/l (as determined during screening). Transfusion in the 2 weeks preceding screening is not allowed.
* Laboratory tests: ASAT/ALAT \<5xULN (upper limit of normal), bilirubine \<1.5xULN, Creatinine value \<1.5xULN, Lactate dehydrogenase value \< ULN and albumin value \> LLN (lower limit of normal).
* Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test just prior to the first study drug administration on Day 1, and must be willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) or true abstinence (when this is in line with the preferred and usual lifestyle)\* during the study and for at least 12 months after the last study drug administration.

  \*True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (such as calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
* Men must be willing to use an effective contraceptive method (e.g. condom, vasectomy) during the study and for at least 12 months after the last study drug administration.
* Ability to return to the hospital for adequate follow-up as required by this protocol.
* Written informed consent according to ICH-GCP.

Exclusion Criteria:

* Medical or psychological impediment to probable compliance with the protocol.
* Abdominal ascites.
* Current or previous use of a CD40 antibody and/or anti-tumor vaccinations.
* Current use of steroids (or other immunosuppressive agents). Patients must have had 6 weeks of discontinuation and must stop any such treatment during the time of the study. Prophylactic usage of dexamethasone during chemotherapy is excluded from this 6 weeks interval.
* Prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has undergone curative intent treatment and has been disease-free for two years.
* Serious concomitant disease, or active infections.
* History of autoimmune disease, organ allografts or active acute or chronic infection, including but not limited to HIV and viral hepatitis.
* Serious intercurrent chronic or acute illness such as pulmonary disease (asthma or COPD), cardiac disease (NYHA class III or IV), hepatic disease or other illness considered by the study coordinator to constitute an unwarranted high risk for the investigational treatment.
* Known allergy to shell fish (may contain keyhole limpet hemocyanin (KLH)).
* Pregnant or lactating women.
* Inadequate vein access to perform leukapheresis.
* Concomitant participation in another clinical intervention trial (except participation in a biobank study).
* An organic brain syndrome or other significant psychiatric abnormality which would compromise the ability to give informed consent, and preclude participation in the full protocol and follow-up.

Primary outcomes:
measure: Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0
timeFrame: From first dose (week 0 of treatment phase) to end of the DLT observation period (week 6 of treatment phase)
Secondary outcomes:
measure: Determine the presence of vaccine-induced dendritic cell mediated immune responses using ELISA and flow cytometry.
timeFrame: From baseline to end of study (week 36)
measure: Determine the intratumoral treatment effect by measuring T cell influx
timeFrame: From baseline to week 6
measure: Determine vaccine-induced changes in the frequency of immune cell subsets using flow cytometry
timeFrame: From baseline to end of study (week 36)
measure: Determining predictive gene expression signatures related to therapy outcome using NanoString technology
timeFrame: From baseline to end of study (week 36)
measure: Radiological response rate as defined by RECIST version 1.1 and iRECIST
timeFrame: From baseline to end of study (week 36)
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus MC
state: Zuid-Holland
Study officials:
affiliation: Erasmus Medical Center
name: Ferry Eskens, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: